Innovent Biologics, a world-class China- based biopharmaceutical company that develops and commercializes high quality drugs, today presented clinical trial data on cohort D of sintilimab clinical studies at the 2018 Annual Meeting of Chinese Society of Clinical Oncology. Based on the efficacy and safety profile from this early phase clinical tri
Gained 285.48% to close Wednesday's trading at $16.46. On September 14, the Company effected a 1 for 30 reverse stock split. On September 4, the Company announced additional positive data from a Phase 2 a study of its NasoVAX intranasal influenza vaccine candidate. Gained 55% to close Wednesday's trading at $8.68.
Surgery, a peer-reviewed journal from the Association of VA Surgeons, Pacific Coast Surgical Association and Surgical Outcomes Club that promotes the art and science of surgery, published nine research articles on the following topics in its August 2018 edition:. *Association of Hospital Participation in a Regional Trauma Quality Improvement...
Purdue University issued the following news release:. A $1.7 million National Science Foundation SBIR Phase I/II grant to a Purdue University- affiliated startup will help fast-track to human trials a novel injectable-targeted drug that shows great promise in accelerating and improving the healing of broken or compromised bones. Novosteo Inc., the.
The study achieved primary endpoint. Navidea Biopharmaceuticals Inc shares climbed 60.06 percent to close at $0.2889 after the company reported acceptance into the National Institutes of Health Commercialization Accelerator Program. Tilray, Inc. surged 28.95 percent to close at $154.98 after the company received US approval to import a medical...
By a News Reporter-Staff News Editor at Biotech Week Advanced Bionics Announces the FDA Approval of the HiRes? Ultra 3 D Cochlear Implant. Built on the HiRes? Ultra platform and developed by the internal Research and Development Team at AB, the new implant is the Hassle Free and Pain Free choice for recipients undergoing MRI examinations. Han
AbbVie Reinforces Leadership in Dermatology With New Data Showcasing Research Advancements Across Growing Portfolio at the 27th European Academy of Dermatology and Venereology EADV Congress. By a News Reporter-Staff News Editor at Biotech Week AbbVie, a research-based global biopharmaceutical company, announced that it will present new data acros
Acasti Pharma Inc., a biopharmaceutical innovator focused on the research, development and commercialization of its prescription drug candidate CaPre for the treatment of severe hypertriglyceridemia, today provided a clinical and market update. Jan DAlvise, president and CEO of Acasti Pharma, commented, I am pleased to report we remain on track wit
TORONTO- Acerus Pharmaceuticals Corporation today announced the publication of a clinical trial update in the journal European Urology Focus on the effects of Natesto on reproductive hormones and semen parameters. This study is being conducted at the University of Miami's Department of Urology, and Dr. Ranjith Ramasamy, MD, the Director of Reproduc
Adverum Biotechnologies, Inc., a clinical-stage gene therapy company targeting unmet medical needs in serious rare and ocular diseases, today announced the U.S. Food and Drug Administration has granted Fast Track designation for ADVM-022. The FDA s Fast Track designation is an important recognition of our ADVM-022 gene therapy program, s
Alector, a privately held biotechnology company pioneering immuno-neurology, a novel therapeutic approach for the treatment of neurodegeneration, today announced the initiation of its Phase 1 trial called INFRONT, which is evaluating AL001, the company s product candidate for the treatment of a genetically-defined sub-population of patients with
AmpliPhi Biosciences Corporation, a clinical-stage biotechnology company focused on precisely targeted bacteriophage therapeutics for antibiotic-resistant infections, today announced that the company has received positive feedback, via written response, from the U.S. Food and Drug Administration regarding its development plans for AB-PA01,...
Amygdala Neurosciences announced today the SEARCH program of Phase 2 clinical studies which are sponsored by the National Institute of Allergy and Infectious Diseases and are being conducted by the NIH Clinical Center and the Institute of Human Virology at the University of Maryland School of Medicine. Henry Masur, Chief of the NIH Critical Care
INTRODUCTION Given the increasing focus on personalized medicine, biologics have established a strong foothold in the pharmaceutical industry. Owing to several beneficial features, such as high specificity, and a favorable safety profile, antibody based pharmacological interventions presently represent the largest class of biologics, with 79...
ApoCell, Inc., a leader in the capture and analysis of circulating tumor cells, announced today the publication of biomarker results from the BEACON Phase 3 clinical trial that utilized Apocell's proprietary circulating tumor cell enrichment system, ApoStream . ApoCell's proprietary ApoStream technology uses a low-level electrical field to capt
ARCA biopharma, Inc., a biopharmaceutical company applying a precision medicine approach to developing genetically-targeted therapies for cardiovascular diseases, today announced that it has submitted a Special Protocol Assessment request to the U.S. Food and Drug Administration. The SPA submission is the next step in beginning a Phase 3 program fo
argenx today announced positive topline results from its Phase 2 proof-of-concept clinical trial of efgartigimod in adult primary immune thrombocytopenia patients. The Phase 2 data of efgartigimod showed a favorable safety and tolerability profile consistent with the Phase 1 healthy volunteer trial and the Phase 2 proof-of-concept trial in...
SINGAPORE- ASLAN Pharmaceuticals, a clinical-stage biopharmaceutical company targeting cancers that are both highly prevalent in Asia and orphan indications in the United States and Europe, today announced an update to its planned timelines for the ongoing single-arm clinical trial in China testing varlitinib plus capecitabine in patients with...
The data were presented today at the European Respiratory Society International Congress 2018 in Paris, France, and published in The Lancet Respiratory Medicine.1. Dr Colin Reisner, Head of Respiratory, Global Medicines, said:' We are encouraged by the results of the KRONOS trial which demonstrate PT010's efficacy in improving lung function and its
"Key Players in the global CTMS market are Oracle Corporation, DATATRAK International, Merge Healthcare, MedNet Solutions, Parexel International Corp., Forte Research Systems, Medidata Solutions and Omnicomm Systems." UK Clinical Trial Management Systems Market will achieve remarkable growth over the forecast time period, driven by favorable govern
Axsome Therapeutics, Inc., a clinical-stage biopharmaceutical company developing novel therapies for the management of central nervous system disorders, today announced that it will host a research and development day with key opinion leaders on Thursday, October 18, 2018 in New York City. The event will feature presentations from Jeffrey Cumming
-Bavarian Nordic- sponsored study has commenced dosing. Study marks the second of three planned Phase 2 combination studies of CV301 with checkpoint inhibitors in solid tumors. COPENHAGEN, Denmark, September 18, 2018- Bavarian Nordic A/S today announced that the first patient has been dosed in a Phase 2 study evaluating the combination therapy of i
BEIJING- BeiGene, Ltd., a commercial-stage biopharmaceutical company focused on developing and commercializing innovative molecularly-targeted and immuno-oncology drugs for the treatment of cancer, today announced four oral clinical data presentations on two of its late-stage investigational therapies, tislelizumab and zanubrutinib, at the 21st...
Benitec Biopharma Limited, a clinical-stage biotechnology company developing novel genetic medicines via the proprietary DNA-directed RNA interference platform combining RNA interference with gene therapy, today announced that Gregory R. Reyes, M.D., Ph.D., has joined the company as Senior Scientific Advisor. Ph.D., Executive Chairman and Chief E